应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01093 石药集团
交易中 02-09 11:30:55
9.800
+0.140
+1.45%
最高
10.090
最低
9.700
成交量
4,781万
今开
9.700
昨收
9.660
日振幅
4.04%
总市值
1,129亿
流通市值
1,129亿
总股本
115.22亿
成交额
4.73亿
换手率
0.41%
流通股本
115.22亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
港股异动 | 石药集团(01093)涨超3% 机构看好公司未来在EGFR ADC及研发平台将有更多对外授权合作机会
智通财经 · 56分钟前
港股异动 | 石药集团(01093)涨超3% 机构看好公司未来在EGFR ADC及研发平台将有更多对外授权合作机会
【券商聚焦】东北证券首予石药集团“买入”评级 指与阿斯利康合作升级加速全球化布局
金吾财讯 · 10:01
【券商聚焦】东北证券首予石药集团“买入”评级 指与阿斯利康合作升级加速全球化布局
生物类似药，卷土重来
医前沿 · 02-07 20:31
生物类似药，卷土重来
康诺亚 TSLP 单抗启动新 III 期，石药拥有权益
丁香园 Insight 数据库 · 02-05
康诺亚 TSLP 单抗启动新 III 期，石药拥有权益
每日卖空追踪 | 石药集团 02月05日卖空量成交747.8万股，卖空比例为9.6%
市场透视 · 02-05
每日卖空追踪 | 石药集团 02月05日卖空量成交747.8万股，卖空比例为9.6%
东方证券：替尔泊肽加冕新“药王” 未来减重药物商业价值将快速释放
智通财经 · 02-05
东方证券：替尔泊肽加冕新“药王” 未来减重药物商业价值将快速释放
4.56个亿！S司给727名员工发钱！
体外诊断网 · 02-05
4.56个亿！S司给727名员工发钱！
石药集团185亿美元合作背后
YOUNG财经 漾财经 · 02-04
石药集团185亿美元合作背后
石药集团02月04日主力净流出7504.9万元 散户资金买入
市场透视 · 02-04
石药集团02月04日主力净流出7504.9万元 散户资金买入
【券商聚焦】招银国际维持石药集团(01093)“买入”评级 指BD交易将成为盈利增长的关键可持续驱动力
金吾财讯 · 02-03
【券商聚焦】招银国际维持石药集团(01093)“买入”评级 指BD交易将成为盈利增长的关键可持续驱动力
每日卖空追踪 | 石药集团 02月03日卖空量成交732.6万股，卖空比例为3.35%
市场透视 · 02-03
每日卖空追踪 | 石药集团 02月03日卖空量成交732.6万股，卖空比例为3.35%
石药集团与阿斯利康达成重磅合作，维持“跑赢行业”评级
中金公司 · 02-03
石药集团与阿斯利康达成重磅合作，维持“跑赢行业”评级
港股异动 | 石药集团(01093)涨近6% 机构预计BD交易将支持公司盈利及派息
智通财经 · 02-03
港股异动 | 石药集团(01093)涨近6% 机构预计BD交易将支持公司盈利及派息
大行评级丨里昂：上调石药集团目标价至19港元，重申“高度确信跑赢大市”评级
中金财经 · 02-03
大行评级丨里昂：上调石药集团目标价至19港元，重申“高度确信跑赢大市”评级
石药集团(01093)：氯维地平乳状注射液获药品注册批件
智通财经 · 02-02
石药集团(01093)：氯维地平乳状注射液获药品注册批件
美银证券：升石药集团(01093)目标价至9.1港元 重申“跑输大市”评级
智通财经 · 02-02
美银证券：升石药集团(01093)目标价至9.1港元 重申“跑输大市”评级
招商证券国际：重申石药集团(01093)“中性”评级 中国创新药进入全球管线
智通财经 · 02-02
招商证券国际：重申石药集团(01093)“中性”评级 中国创新药进入全球管线
港股石药集团(01093.HK)早盘涨超5%
每日经济新闻 · 02-02
港股石药集团(01093.HK)早盘涨超5%
中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级
智通财经 · 02-02
中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级
签下185亿美元超级大单，石药为何反遭抛售？“聪明钱”悄然借道港股通创新药ETF（520880）埋伏
新浪基金 · 02-01
签下185亿美元超级大单，石药为何反遭抛售？“聪明钱”悄然借道港股通创新药ETF（520880）埋伏
加载更多
公司概况
公司名称：
石药集团
所属市场：
SEHK
上市日期：
--
主营业务：
石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":9.8,"timestamp":1770607850586,"preClose":9.66,"halted":0,"volume":47807584,"delay":0,"changeRate":0.014492753623188465,"floatShares":11522000000,"shares":11522000000,"eps":0.41564150220749685,"marketStatus":"交易中","change":0.14,"latestTime":"02-09 11:30:55","open":9.7,"high":10.09,"low":9.7,"amount":472775666,"amplitude":0.040373,"askPrice":9.81,"askSize":208000,"bidPrice":9.8,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":0.39932665058254474,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770609600000},"marketStatusCode":2,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":9.66,"dividendRate":0.024469,"openAndCloseTimeList":[[1770600600000,1770609600000],[1770613200000,1770624000000]],"volumeRatio":0.875515,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1772035200000,"strike":"10.50","timestamp":1770602358224,"price":0.21,"volume":1000,"amount":420000,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1772035200000,"strike":"10.50","timestamp":1770602358224,"price":0.21,"volume":500,"amount":210000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.5372,"impliedVolPercentile":0.5301},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2610502918","title":"港股异动 | 石药集团(01093)涨超3% 机构看好公司未来在EGFR ADC及研发平台将有更多对外授权合作机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2610502918","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610502918?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:35","pubTimestamp":1770604509,"startTime":"0","endTime":"0","summary":"消息面上，汇丰研究发布研究报告指出，石药集团股价年初至今累计上涨约9%，在1月30日公布与阿斯利康的合作前已升14%，目前认为其估值仍然吸引，并憧憬未来在EGFR ADC及研发平台将有更多对外授权合作机会，计及预付款及上季销售轻微改善的预期，将2025至2027年收入预测上调3%至11%。该行并将石药集团2025至2027年净利润预测上调7%至18%，认为对外授权收入的增长已能抵销药品集中带量采购政策所带来的负面影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","IE00B543WZ88.USD","LU0315179316.USD","LU1960683339.HKD","BK4080","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","IE0008369823.USD","01093","BK4585","BK4588","LU1226288170.HKD","LU1226288253.USD","LU1813983027.USD","LU0880133367.SGD","BK1521","LU0326950275.SGD","LU0067412154.USD","ADC","BK1191","LU1152091168.USD","LU1226287875.USD","LU0501845795.SGD","LU1951186391.HKD","LU0140636845.USD","LU0314109678.HKD","BK1515","LU1008478684.HKD","LU1226287529.USD","LU1226287792.SGD","SG9999004220.SGD","LU1152091754.HKD","LU1993786604.SGD","VXUS","HK0000165453.HKD","LU1328277881.USD","LU1807302812.USD","VT","LU0072913022.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK4231"],"gpt_icon":0},{"id":"2610502281","title":"【券商聚焦】东北证券首予石药集团“买入”评级 指与阿斯利康合作升级加速全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2610502281","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610502281?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:01","pubTimestamp":1770602516,"startTime":"0","endTime":"0","summary":"金吾财讯|东北证券发布研报指，石药集团与阿斯利康签订战略研发合作与授权协议，围绕长效多肽与AI制药技术平台展开合作，潜在交易总金额达185亿美元。研报指出，公司核心技术平台实现突破，其缓释给药技术可使多肽药物给药间隔达每月一次，多肽药物AI发现平台能快速设计优化候选分子。公司构建覆盖抗肿瘤、心脑血管等核心赛道的研发格局，多项资产获跨国药企认可。给予“买入”评级，风险提示包括研发进展不及预期等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102357a6e400a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102357a6e400a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093"],"gpt_icon":0},{"id":"2609527492","title":"生物类似药，卷土重来","url":"https://stock-news.laohu8.com/highlight/detail?id=2609527492","media":"医前沿","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609527492?lang=zh_cn&edition=full","pubTime":"2026-02-07 20:31","pubTimestamp":1770467497,"startTime":"0","endTime":"0","summary":"在当前创新药高举高打的热潮下，生物类似药似乎在角落中再次萌芽，迎来了新的生机。粗略检索CDE受理品种信息，国内生物药3.3类生物类似药申报数量达到了26项，自2025年以来增速显著。这些都是生物类似药研发的主流企业，都有多款产品获批上市。成都康弘通过布局IL-4R和PD-1两项爆款生物类似药，快速重启生物新药研发，与两款双抗双毒素ADC创新管线交相辉映，在创新药的不确定性中寻找确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207204301a4881bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207204301a4881bd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","HK0000165453.HKD","LU2097828714.EUR","02696","LU1969619763.USD","LU2488822045.USD","LU2097828631.EUR","LU2097828805.USD","LU2328871848.SGD","LU2242644610.SGD","LU2097828557.USD","LU0502904849.HKD","LU2097828474.EUR","01093","LU0455707207.USD","01801","BK1589"],"gpt_icon":0},{"id":"2609133589","title":"康诺亚 TSLP 单抗启动新 III 期，石药拥有权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2609133589","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609133589?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:12","pubTimestamp":1770282749,"startTime":"0","endTime":"0","summary":"TSLP 是炎症级联反应的启动因子之一，抑制 TSLP 可以从炎症发生的早期进行干预，阻止免疫细胞释放促炎细胞因子。其中哮喘已经推进至 III 期临床研究。2021 年 11 月，康诺亚与石药集团达成合作，将 CM326 在中重度哮喘和慢性阻塞性肺病等呼吸系统疾病开发及商业化权益独家授予后者。2024 年 11 月，康诺亚同意扩大授予石药集团的特许权使用领域至所有适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0326950275.SGD","BK1515","LU1993786604.SGD","IE00B031HY20.USD","LU1226288170.HKD","BK1574","BK1191","LU1328277881.USD","LU0315179316.USD","LU0140636845.USD","LU1226287529.USD","BK1583","IE0008369823.USD","LU0501845795.SGD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1807302812.USD","LU0067412154.USD","LU0314109678.HKD","BK1161","LU0072913022.USD","IE00BZ08YR35.GBP","02162","IE00B5MMRT66.SGD","01093","LU1813983027.USD","LU1152091754.HKD","LU1960683339.HKD","HK0000165453.HKD","SG9999004220.SGD","LU1226287792.SGD","LU0880133367.SGD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1152091168.USD","BK1521","LU1008478684.HKD","BK1587","LU2039709279.SGD","IE00B543WZ88.USD","LU1226288253.USD","LU1226287875.USD"],"gpt_icon":0},{"id":"2609370732","title":"每日卖空追踪 | 石药集团 02月05日卖空量成交747.8万股，卖空比例为9.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609370732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609370732?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:30","pubTimestamp":1770280218,"startTime":"0","endTime":"0","summary":"石药集团北京时间02月05日，涨0.52%，卖空量成交747.8万股，较上一交易日减少60.02%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163349a47f5fc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163349a47f5fc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2039709279.SGD","LU1152091754.HKD","LU1226287875.USD","BK1515","LU1008478684.HKD","LU0326950275.SGD","01093","LU0067412154.USD","IE00B031HY20.USD","LU0314109678.HKD","BK1191","LU1951186391.HKD","LU1960683339.HKD","IE0008369823.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1226288253.USD","LU1226288170.HKD","LU1813983027.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287792.SGD","BK1521","LU1993786604.SGD","LU0501845795.SGD","LU0140636845.USD","HK0000165453.HKD","LU1226287529.USD","LU1328277881.USD","LU0072913022.USD","LU0315179316.USD"],"gpt_icon":0},{"id":"2609273347","title":"东方证券：替尔泊肽加冕新“药王” 未来减重药物商业价值将快速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2609273347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609273347?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:38","pubTimestamp":1770269908,"startTime":"0","endTime":"0","summary":"当前，MNC已将减重视为核心的战略要地，大额BD和并购频现，今年催化密集。东方证券主要观点如下：替尔泊肽加冕“药王”，减重药物将霸榜2026年2月4日，礼来发布2025年业绩，替尔泊肽全年销售365.07亿美元，加冕2025年全球“药王”，并有望多年蝉联。据Evaluate预测，到2030年全球销售额前十药物中约半数为GLP-1类药物。减重BD未停，新方向需求将起去年末以来，减重领域交易仍在持续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0072913022.USD","HK0000165453.HKD","LU0067412154.USD","BK0188","BK1574","LU0326950275.SGD","LU0880133367.SGD","BK0276","LU1226287529.USD","LU0501845795.SGD","LU1328277881.USD","LU1807302812.USD","IE00B543WZ88.USD","BK1147","LU2039709279.SGD","01093","LU1951186391.HKD","BK0012","IE00BZ08YR35.GBP","IE0008369823.USD","LU1993786604.SGD","IE0008368742.USD","LU1813983027.USD","SG9999004220.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU1008478684.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","BK0183","BK1161","BK1521","600958","LU1226287875.USD","03958","BK1191","IE00B5MMRT66.SGD","LU0315179316.USD","BK1515","LU1152091168.USD","BK1564","LU0140636845.USD","BK0028","01672","IE00B031HY20.USD","LU1960683339.HKD","LU0314109678.HKD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2609707683","title":"4.56个亿！S司给727名员工发钱！","url":"https://stock-news.laohu8.com/highlight/detail?id=2609707683","media":"体外诊断网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609707683?lang=zh_cn&edition=full","pubTime":"2026-02-05 12:07","pubTimestamp":1770264466,"startTime":"0","endTime":"0","summary":"来源：企业公告 整理：体外诊断网1月23日，港股上市公司石药集团发布自愿公告，宣布根据其限制性股份奖励计划，向集团内727名获选雇员无偿授予合共46,462,500股限制性股份。以授出日收市价每股9.81港元计算，此次授予股份总价值约4.56亿港元。本次授予的奖励股份数量约占公司已发行股份总数的0.4%。石药集团强调，该计划属于《上市规则》第17章所规范的涉及现有股份的股份计划，相关披露符合监管要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205123959953fe932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205123959953fe932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","LU1226287792.SGD","LU1226288170.HKD","LU0315179316.USD","LU1152091754.HKD","LU1951186391.HKD","LU1328277881.USD","IE00BZ08YT58.USD","LU1008478684.HKD","LU0067412154.USD","IE00B031HY20.USD","01093","LU1226287529.USD","LU1807302812.USD","LU1960683339.HKD","BK1521","IE0008368742.USD","LU0140636845.USD","LU1813983027.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1226287875.USD","LU0501845795.SGD","SG9999004220.SGD","IE00B543WZ88.USD","LU0072913022.USD","LU1993786604.SGD","LU1226288253.USD","BK1191","IE0008369823.USD","LU0326950275.SGD","LU0880133367.SGD","LU2039709279.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1152091168.USD"],"gpt_icon":0},{"id":"2609539158","title":"石药集团185亿美元合作背后","url":"https://stock-news.laohu8.com/highlight/detail?id=2609539158","media":"YOUNG财经 漾财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609539158?lang=zh_cn&edition=full","pubTime":"2026-02-04 19:35","pubTimestamp":1770204920,"startTime":"0","endTime":"0","summary":"石药集团185亿美元合作背后王琳1月30日早间，石药集团重磅宣布，与阿斯利康签订战略研发合作与授权协议，以利用石药集团专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。交易总额高达185亿美元。2025年6月，石药集团与阿斯利康达成一项潜在金额超53亿美元的战略合作，聚焦AI驱动的新型口服小分子候选药物开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020421474697a4ddc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020421474697a4ddc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226288170.HKD","LU1960683339.HKD","LU0326950275.SGD","LU1226287529.USD","LU1226288253.USD","LU2039709279.SGD","LU0501845795.SGD","LU0140636845.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1813983027.USD","HK0000165453.HKD","LU0314109678.HKD","BK1191","BK1521","LU1152091168.USD","IE00B031HY20.USD","IE0008369823.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU0880133367.SGD","LU0067412154.USD","LU1152091754.HKD","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1807302812.USD","LU0315179316.USD","LU1951186391.HKD","SG9999004220.SGD","LU1993786604.SGD","LU1226287875.USD","IE0008368742.USD","01093","LU0072913022.USD","BK1515"],"gpt_icon":0},{"id":"2609739158","title":"石药集团02月04日主力净流出7504.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2609739158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609739158?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:15","pubTimestamp":1770192950,"startTime":"0","endTime":"0","summary":"02月04日, 石药集团股价跌2.02%，报收9.69元，成交金额9.5亿元，换手率0.85%，振幅4.35%，量比0.35。石药集团今日主力资金净流出7504.9万元，上一交易日主力净流入6205.0万元。该股近5个交易日下跌7.68%，主力资金累计净流出3553.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入6.1亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204162105a6d1f32e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204162105a6d1f32e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","LU1807302812.USD","BK1521","LU0140636845.USD","LU0315179316.USD","LU0326950275.SGD","LU1152091754.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1008478684.HKD","LU2039709279.SGD","LU0072913022.USD","LU1226288170.HKD","LU1960683339.HKD","LU1152091168.USD","LU0314109678.HKD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1328277881.USD","IE00B543WZ88.USD","BK1515","LU1993786604.SGD","LU1226287529.USD","SG9999004220.SGD","LU1813983027.USD","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1226288253.USD","LU0501845795.SGD","01093","LU1226287875.USD","IE0008369823.USD","IE0008368742.USD","BK1191"],"gpt_icon":0},{"id":"2608829585","title":"【券商聚焦】招银国际维持石药集团(01093)“买入”评级 指BD交易将成为盈利增长的关键可持续驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2608829585","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608829585?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:04","pubTimestamp":1770109496,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，石药集团 与阿斯利康达成战略合作，共同推进八个体重管理和2型糖尿病项目。石药集团报告2025年前9个月总收入为199亿元人民币，其中包含15.4亿元人民币的对外授权收入。剔除BD贡献后，核心收入为184亿元人民币，同比下降19%。得益于近期BD交易的首付款支持，该机构还预计公司将维持可持续的股息派发。维持“买入”评级。石药集团的BD交易将成为盈利增长的关键可持续驱动力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974494","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"gpt_icon":0},{"id":"2608870184","title":"每日卖空追踪 | 石药集团 02月03日卖空量成交732.6万股，卖空比例为3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608870184?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:30","pubTimestamp":1770107418,"startTime":"0","endTime":"0","summary":"石药集团北京时间02月03日，涨8.09%，卖空量成交732.6万股，较上一交易日减少66.84%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163307a476c08c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163307a476c08c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","LU0067412154.USD","HK0000165453.HKD","LU1226288253.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1226287875.USD","BK1515","LU1960683339.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0315179316.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU0326950275.SGD","LU0314109678.HKD","IE0008369823.USD","SG9999004220.SGD","LU2039709279.SGD","LU1813983027.USD","LU1226288170.HKD","LU1951186391.HKD","LU0072913022.USD","LU1226287529.USD","BK1191","IE0008368742.USD","01093","LU0501845795.SGD","IE00B031HY20.USD","BK1521","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1807302812.USD","LU1152091168.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2608870979","title":"石药集团与阿斯利康达成重磅合作，维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608870979","media":"中金公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608870979?lang=zh_cn&edition=full","pubTime":"2026-02-03 14:10","pubTimestamp":1770099046,"startTime":"0","endTime":"0","summary":"此次调整基于石药集团与阿斯利康签署的研发合作与授权协议，标志着中国创新药授权出海取得里程碑式突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203142137a6cd3406&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203142137a6cd3406&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093"],"gpt_icon":0},{"id":"2608841857","title":"港股异动 | 石药集团(01093)涨近6% 机构预计BD交易将支持公司盈利及派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2608841857","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608841857?lang=zh_cn&edition=full","pubTime":"2026-02-03 13:38","pubTimestamp":1770097100,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团涨近6%，截至发稿，涨5.9%，报9.69港元，成交额11.73亿港元。消息面上，里昂发布研报称，预计石药集团的业务发展交易将自2026年起转化为经常性收入。公司与阿斯利康及Madrigal Pharmaceuticals签订的协议，预计短期内可为石药集团带来约102亿美元的预付款及研发里程碑付款，推动2025至27财年盈利显著提升至63亿、102亿及109亿元人民币。该行认为BD交易将成为公司盈利增长的持续推动力，并支持派息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1993786604.SGD","BK1191","LU0067412154.USD","LU1226287792.SGD","LU1960683339.HKD","01093","LU0072913022.USD","IE00BZ08YR35.GBP","VT","IE0008368742.USD","LU0880133367.SGD","LU1328277881.USD","IE00B031HY20.USD","LU0326950275.SGD","LU1807302812.USD","LU1226288170.HKD","SG9999004220.SGD","IE0008369823.USD","LU1813983027.USD","LU0140636845.USD","LU0314109678.HKD","BK1521","BK4585","LU0315179316.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","IE00BZ08YT58.USD","BK4588","BK1515","LU1152091168.USD","LU0501845795.SGD","LU1226288253.USD","LU1152091754.HKD","LU2039709279.SGD","LU1008478684.HKD","HK0000165453.HKD","IE00B543WZ88.USD","LU1226287875.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2608843874","title":"大行评级丨里昂：上调石药集团目标价至19港元，重申“高度确信跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608843874","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608843874?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:17","pubTimestamp":1770088621,"startTime":"0","endTime":"0","summary":"里昂发表研报指，预期石药集团目前已完成的业务拓展(BD)交易，将自今年起转化为经常性收入。与阿斯利康及Madrigal Pharmaceuticals达成的4项重大BD交易，预计将带来约102亿美元的近期首付款及研发里程碑付款，从而推动2025至27年盈利大幅提升至63亿、102亿及109亿元。该行将2025至27年盈利预测分别下调2.4%、上调8.2%及上调53.7%，以反映BD交易经风险调整后的财务影响。该行重申石药“高度确信跑赢大市”评级，目标价由17.4港元上调至19港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260203/31994071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01093"],"gpt_icon":0},{"id":"2608865380","title":"石药集团(01093)：氯维地平乳状注射液获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2608865380","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608865380?lang=zh_cn&edition=full","pubTime":"2026-02-02 19:42","pubTimestamp":1770032533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的氯维地平乳状注射液已获得中国国家药品监督管理局颁发的药品注册批件。该产品是二氢吡啶类钙通道阻滞拮抗剂，属于速效静脉降压药，适用于治疗不适宜口服或预期口服药物治疗效果不佳的高血压患者。该产品的获批将进一步丰富集团在心脑血管疾病治疗领域的产品管线，提升集团在该领域的竞争力，并有望填补高血压急症用药的临床需求空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：氯维地平乳状注射液获药品注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0067412154.USD","LU0072913022.USD","LU1807302812.USD","LU1226288253.USD","LU1993786604.SGD","BK1191","BK1515","IE0008369823.USD","IE00B031HY20.USD","LU1960683339.HKD","LU0314109678.HKD","BK1521","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1152091168.USD","LU1008478684.HKD","LU1226287792.SGD","IE00B543WZ88.USD","LU1226287875.USD","LU0880133367.SGD","01093","IE0008368742.USD","LU2039709279.SGD","LU0315179316.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1328277881.USD","LU1951186391.HKD","IE00BZ08YT58.USD","SG9999004220.SGD","HK0000165453.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1813983027.USD","LU1226288170.HKD","LU1152091754.HKD","LU0140636845.USD"],"gpt_icon":0},{"id":"2608830853","title":"美银证券：升石药集团(01093)目标价至9.1港元 重申“跑输大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608830853","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608830853?lang=zh_cn&edition=full","pubTime":"2026-02-02 15:05","pubTimestamp":1770015943,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，将石药集团目标价由8.5港元上调至9.1港元，但重申“跑输大市”评级，因认为集团现有产品组合面临销售压力，且研发管线短期贡献有限，大多数关键资产仍处于早期阶段。报告指，石药集团与阿斯利康合作达成协议，开发创新长效多肽药物，协议总价值最高可达185亿美元。该行指，石药集团于去年5月公布将有3项潜在对外授权交易，是次协议应为第二项落实的交易，而落实时间较预期延迟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","161027"],"gpt_icon":0},{"id":"2608836458","title":"招商证券国际：重申石药集团(01093)“中性”评级 中国创新药进入全球管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2608836458","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608836458?lang=zh_cn&edition=full","pubTime":"2026-02-02 10:50","pubTimestamp":1770000610,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研报称，石药集团与阿斯利康达成历史性交易公告，表示看好交易，但需等待石药或阿斯利康披露更多长效GLP-1全球开发细节。重申“中性”评级，认为短期基本面仍存隐忧。该行表示，根据石药最新公告，与阿斯利康合作的关键临床候选药物为SYH2082，长效GLP-1R/GIPR双激动剂，现已进入I期临床。该行认为siRNA进入肥胖维持市场，将对所有胜肽类方案构成真正威胁。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","159992","01093","06099"],"gpt_icon":0},{"id":"2608835381","title":"港股石药集团(01093.HK)早盘涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608835381","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608835381?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:59","pubTimestamp":1769997544,"startTime":"0","endTime":"0","summary":"每经AI快讯，石药集团(01093.HK)早盘涨超5%，截至发稿，涨2.19%，报9.81港元，成交4.46亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638288537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638288537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","LU0314109678.HKD","LU1008478684.HKD","LU0072913022.USD","LU0140636845.USD","LU1226287875.USD","01093","VT","LU0501845795.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1226288253.USD","HK0000165453.HKD","LU1328277881.USD","BK4588","LU1960683339.HKD","IE00B543WZ88.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1807302812.USD","IE0008368742.USD","IE00BZ08YT58.USD","LU2039709279.SGD","BK1191","LU0067412154.USD","LU1226287529.USD","BK4585","LU1152091168.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","LU1152091754.HKD","LU1226287792.SGD","LU1951186391.HKD","LU0315179316.USD","SG9999004220.SGD","LU1813983027.USD","IE0008369823.USD","IE00B031HY20.USD","BK1521"],"gpt_icon":0},{"id":"2608833532","title":"中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833532","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608833532?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:37","pubTimestamp":1769996220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持石药集团“跑赢行业”评级，考虑对外授权持续兑现上调目标价9.1%到12港元。石药集团公告与阿斯利康签订研发合作与授权协议。中金主要观点如下：中国创新药授权出海再获里程碑式突破根据公告，石药集团及附属公司授权阿斯利康在全球范围内独家开发、生产和商业化8个创新长效多肽药物项目，阿斯利康将支付合计12亿美元预付款以及后续累计最高35亿/138亿美元的开发/销售里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","AZN"],"gpt_icon":0},{"id":"2608405007","title":"签下185亿美元超级大单，石药为何反遭抛售？“聪明钱”悄然借道港股通创新药ETF（520880）埋伏","url":"https://stock-news.laohu8.com/highlight/detail?id=2608405007","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608405007?lang=zh_cn&edition=full","pubTime":"2026-02-01 19:37","pubTimestamp":1769945820,"startTime":"0","endTime":"0","summary":"中国创新药出海BD再获里程碑式突破！ 1月30日，石药集团宣布已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议，以利用集团专有的缓释给药技术平台及多肽药物AI发现平台，开发创新长效多肽药物。若后续所有研发及销售里程碑均达成，石药集团方面有权获得总计高达185亿美元的款项。其12亿美元的预付款，仅次于此前三生制药与辉瑞就PD-1/VEGF达成的数额。此前10日，520880累获逾2.74亿元资金净申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-01/doc-inhkihyz4934390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1807302812.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU1328277881.USD","LU0140636845.USD","LU1152091754.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0501845795.SGD","LU1226287529.USD","LU0067412154.USD","IE00BZ08YT58.USD","LU1813983027.USD","BK1515","IE00B5MMRT66.SGD","LU0315179316.USD","HK0000165453.HKD","LU0072913022.USD","LU1226288253.USD","LU1008478684.HKD","LU0880133367.SGD","BK1191","IE00B543WZ88.USD","LU0326950275.SGD","IE0008369823.USD","LU1226288170.HKD","LU1951186391.HKD","IE0008368742.USD","LU0314109678.HKD","LU1152091168.USD","IE00B031HY20.USD","LU1960683339.HKD","SG9999004220.SGD","520880","BK1521","01093","LU1226287875.USD","LU1226287792.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":0.0592},{"period":"3month","weight":0.3089},{"period":"6month","weight":-0.044},{"period":"1year","weight":1.1742},{"period":"ytd","weight":0.1459}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.093906},{"month":3,"riseRate":0.483871,"avgChangeRate":0.020489},{"month":4,"riseRate":0.612903,"avgChangeRate":0.062074},{"month":5,"riseRate":0.612903,"avgChangeRate":0.047434},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}